HomeCompareCLVS vs GIS

CLVS vs GIS: Dividend Comparison 2026

CLVS yields 2463.05% · GIS yields 6.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVS wins by $70041530665.24M in total portfolio value
10 years
CLVS
CLVS
● Live price
2463.05%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$70041530665.32M
Annual income
$64,861,296,013,860,630.00
Full CLVS calculator →
GIS
GIS
● Live price
6.55%
Share price
$37.11
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.2K
Annual income
$16,311.42
Full GIS calculator →

Portfolio growth — CLVS vs GIS

📍 CLVS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVSGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVS + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVS pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVS
Annual income on $10K today (after 15% tax)
$209,359.61/yr
After 10yr DRIP, annual income (after tax)
$55,132,101,611,781,540.00/yr
GIS
Annual income on $10K today (after 15% tax)
$556.59/yr
After 10yr DRIP, annual income (after tax)
$13,864.71/yr
At 15% tax rate, CLVS beats the other by $55,132,101,611,767,670.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVS + GIS for your $10,000?

CLVS: 50%GIS: 50%
100% GIS50/50100% CLVS
Portfolio after 10yr
$35020765332.70M
Annual income
$32,430,648,006,938,470.00/yr
Blended yield
92.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CLVS right now

CLVS
Analyst Ratings
11
Buy
10
Hold
4
Sell
Consensus: Buy
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.8% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVS buys
0
GIS buys
12
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$GIS▼ Sell$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$GIS▲ Buy$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$GIS▲ Buy$1,001 - $15,0002025-09-29
Dan Newhouse🏢 House$GIS▲ Buy$1,001 - $15,0002025-08-18
Gilbert Cisneros🏢 House$GIS▼ Sell$1,001 - $15,0002025-08-05
Ro Khanna🏢 House$GIS▲ Buy$1,000 - $15,0002025-08-04
Ro Khanna🏢 House$GIS▲ Buy$1,001 - $15,0002025-07-24
Lisa McClain🏢 House$GIS▼ Sell$1,001 - $15,0002025-07-16
Lisa McClain🏢 House$GIS▲ Buy$1,001 - $15,0002025-07-10
Gilbert Cisneros🏢 House$GIS▲ Buy$1,001 - $15,0002025-07-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVSGIS
Forward yield2463.05%6.55%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$70041530665.32M$79.2K
Annual income after 10y$64,861,296,013,860,630.00$16,311.42
Total dividends collected$69679216448.03M$51.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: CLVS vs GIS ($10,000, DRIP)

YearCLVS PortfolioCLVS Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$257,005$246,305.42$11,504$804.11+$245.5KCLVS
2$6,191,054$5,916,058.62$13,371$1,061.65+$6.18MCLVS
3$139,814,248$133,189,820.21$15,723$1,416.15+$139.80MCLVS
4$2,960,686,816$2,811,085,570.49$18,735$1,911.16+$2960.67MCLVS
5$58,800,787,025$55,632,852,131.69$22,660$2,613.51+$58800.76MCLVS
6$1,095,531,336,986$1,032,614,494,869.48$27,874$3,627.81+$1095531.31MCLVS
7$19,152,484,228,807$17,980,265,698,231.36$34,947$5,121.52+$19152484.19MCLVS
8$314,266,670,684,876$293,773,512,560,052.56$44,762$7,369.21+$314266670.64MCLVS
9$4,841,340,795,759,426$4,505,075,458,126,609.00$58,728$10,832.80+$4841340795.70MCLVS
10$70,041,530,665,323,210$64,861,296,013,860,630.00$79,151$16,311.42+$70041530665.24MCLVS

CLVS vs GIS: Complete Analysis 2026

CLVSStock

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full CLVS Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this CLVS vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVS vs SCHDCLVS vs JEPICLVS vs OCLVS vs KOCLVS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.